Powerhouse Ventures Ltd. · ASX:PVL
Powerhouse Ventures — Shareholder Meeting (December 2016)
20 slides from Powerhouse Ventures's shareholder meeting presentation, Dec 16, 2016
Slide 1: Managing Director's Address
For personal use only Managing Director’s Address Dr. Stephen Hampson
Slide 2: Systematically creating global businesses from intellectual property
For personal use only Systematically creating global businesses from intellectual property
Slide 3: Highlights of FY16
Highlights of FY16 For personal use only 8m $ .7 Net portfolio value up by $8.7m (73%) Increase in portfolio fair value Four more companies added Led substantial funding round for HydroWorks Investments made across 19 15 companies Deal flow from Australia Four new companies IPO completed 12 October
Slide 4: Enhancing our skill base
Enhancing our skill base For personal use only Appointment of seasoned advisors to Powerhouse on a consulting basis Terrence Rohan, ICT Richard Mander, ICT Colin Harvey, Agritech Index Ventures, San Francisco, California ikeGPS, Seattle Area ANIDEA Consulting Ltd New Zealand Previous: YouTube, Googl
Slide 5: Financial highlights
Financial highlights For personal use only $3.2 m invested across 15 companies Net fair value gains of $5.5m Net portfolio value increase by $8.7m to $20.7m (2015: $12.0m) Pre tax profit of $2.1m (2015: loss of $763k) Net assets of $19.7m (2015: $13.9m) Revenue $8.0m (2015: $4.0m)
Slide 6: Portfolio Growth
$20.7m For personal use only Portfolio Growth The Powerhouse portfolio fair value has grown at an average rate of 35% year-on-year. $12.0m $6.3m $4.7m $2.3m $1.3m Fair Value $0.4m Capital invested Existing portfolio 2010 2011 2012 2013 2014 2015 2016
Slide 7: Fair value movements
Fair value movements For personal use only Total net fair value gains of $5.8m including: $1.8m in CropLogic $3.2m in Invert Robotics $0.8m in Motim Net fair value gains offset by minor fair value losses including: $88k in HydroWorks $237k in Modlar Resulting net portfolio uplift of $5.5m
Slide 8: Our Valuation Policy
Our Valuation Policy For personal use only Total Portfolio $20.7m Sectors of Valuation $0.6m (3%) valued on mark-to-market at 30 June 2016 Quoted$0.6m At cost$3.1m $3.1m (15%) valued at cost Recent funding round$16.9m $16.9m (82%) valued at recent funding round
Slide 9: Investment Portfolio
Investment Portfolio For personal use only Maturing portfolio Diversified portfolio Medical and Pre-Seed$1.8m 8.8% Healthcare $1.5m 7.5% Agritech and Seed$3.9m 18.9% Environmental $8.0m 38.5% Post-Seed$14.9m 72.3% Information and Communication Technologies $3.0m 14.6% Cleantech and Engineering $8.1m
Slide 10: Cleantech sub-sector companies; $8.1 million
Cleantech sub-sector For personal use only 6 companies; $8.1 million Photonics $0.43m 5.3% Koti $0.26m 3.1% Syft $0.60m 7.4% HydroWorks $4.3m 53.0% SolarBright $1.0m 12.8% ArcActive $1.5m 18.4%
Slide 11: ICT and digital sub-sector companies; $3.0 million
ICT and digital sub-sector For personal use only 4 companies; $3.0 million Fluent $0.16m 5.3% Modlar $0.6m 21.4% Motim $2.2m 73.3%
Slide 12: Medical sub-sector companies; $1.5 million
Medical sub-sector For personal use only 6 companies; $1.5 million AuramerBio $0.10m 6.5% Hi-Aspect $0.05m 3.2% Upstream $0.15m 9.7% Mars $0.73m 47.1% Avalia $0.20m 12.9% Tiro $0.32m 20.6%
Slide 13: Agritech sub-sector companies; $8.0 million
Agritech sub-sector For personal use only 5 companies; $8.0 million Veritide $0.65m 8.1% CertusBio $0.15m 1.9% CropLogic $3.2m 40.6% Invert $3.9m 49.3%
Slide 14: Maturing portfolio
Maturing portfolio For personal use only Five companies have enterprise value of over $10m Conservative IPEV valuations produce significant potential upside Total Value $20.7 million Syft $0.6m3% Other $1.8m9% Veritide $0.6m3% Modlar $0.6m3% HydroWorks $4.3m21% Mars $0.7m3% SolarBright $1.0m5% Inver
Slide 15: Outlook
Outlook For personal use only We have a number of companies in our portfolio with the potential to complete an ASX listing Expansion of activity in Australia Maintain focus on our Patient Capital model and long-term value creation for shareholders Significant news flow from the portfolio over the ne
Slide 16: AuramerBio
For personal use only AuramerBio is an aptamer AuramerBio development company founded on DNA aptamers provide technology from Victoria University a fully synthetic, reliable of Wellington (VUW). It specialises biological sensing chemistry in the translation of DNA aptamer to address the under served
Slide 17: Hi-Aspect
For personal use only Hi-Aspect is developing a range Hi-Aspect of new specialty ingredients for Hi-Aspect specialises topical application in the skincare in the development of and medical industries, based on protein-based material its protein fibril technology. and products for the Medical and Lif
Slide 18: Avalia Immunotherapies
For personal use only A patient’s fight against cancer and Avalia infectious disease is being aided by Immunotherapies new vaccines under development The platform technology by Avalia Immunotherapies. can be used to design new treatments for cancer, Avalia is a pre-clinical stage company infectious
Slide 19: Upstream Medical Technologies
For personal use only Upstream Medical Technologies Upstream Medical will be a provider of definitive Technologies front line testing in hospital The company has a platform emergency departments. A suite of cardio endocrine biomarkers of novel biomarkers developed in that accurately diagnose a the C
Slide 20: Annual General Meeting
For personal use only Annual General Meeting
Powerhouse Ventures — Shareholder Meeting (December 2016) on 6ix